Mankind Pharma Ltd
Mankind Pharma Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements. BSV business margins expected to improve by ~100 bps annually over next 2-3 years, targeting 30% margins in 5 years.
From Mankind Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements.
- Organic domestic growth is expected to continue, with Q3 FY25 showing 8.4% domestic growth and 43% export growth.
- Chronic segment is growing faster and gaining share, currently at 37.6% of sales, up 200 bps YoY.
- BSV business integration is underway with expectations of a flat to single-digit growth in FY25; post restructuring, growth should recover.
- The company targets 15%+ growth for BSV portfolio over the next two years, driven by high entry barriers and specialty products.
2 more points from Mankind Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex spends for 9M FY'25 were INR344 crores, which is 3.7% of total revenue, aligning with guidance of 4%-5%.
- Strategic investments include the acquisition of BSV to expand into high entry barrier portfolios and specialty R&D tech platforms.
- The company raised INR10,000 crores through NCDs and CPs for the BSV acquisition and INR3,000 crores in equity used to repay CPs, showing financial discipline.
- Future investments include ongoing R&D initiatives to enter semi-regulated and regulated markets, supporting margin improvement in BSV business.
2 more points from Mankind Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Mankind Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹3.4K Cr, net profit ₹559 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Mankind Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mankind Pharma Ltd Q3 FY25 results?
Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements. BSV business margins expected to improve by ~100 bps annually over next 2-3 years, targeting 30% margins in 5 years.
What is Mankind Pharma Ltd share price analysis?
Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 47.0 with a market cap of ₹100,160 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma Ltd planning capital expenditure?
Capex spends for 9M FY'25 were INR344 crores, which is 3.7% of total revenue, aligning with guidance of 4%-5%.
Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.